<DOC>
	<DOC>NCT01147302</DOC>
	<brief_summary>The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).</brief_summary>
	<brief_title>A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Inclusion Criteria include: ≥18 years of age. Weigh ≥50 kg. Donor specific antibody identified. Exclusion Criteria include: Any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results. History of allergic reaction to C1 Esterase Inhibitor or other blood products. Participation in the active dosing phase of any other investigational drug study within 30 days prior to dosing with study drug. Pregnancy or lactation. Receipt of any experimental agents for AMR within 1 month prior to the first dose of study drug. Any infection that causes hemodynamic compromise. History of bleeding or clotting abnormality.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>